The Burden of (Neuro)Cysticercosis Among People Living With HIV in Rural Tanzania
CYSTINET_Tz
1 other identifier
observational
2,584
1 country
1
Brief Summary
This study aims to compare the burden of neurocysticercosis among people living with HIV to people not infected with HIV.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2018
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2018
CompletedFirst Submitted
Initial submission to the registry
February 4, 2019
CompletedFirst Posted
Study publicly available on registry
February 22, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
April 30, 2021
CompletedNovember 29, 2023
November 1, 2023
3.1 years
February 4, 2019
November 27, 2023
Conditions
Outcome Measures
Primary Outcomes (2)
Prevalence of cysticercosis
Prevalence of cysticercosis among people living with HIV and matched HIV-negative individuals in rural Tanzania where pig farming is common
Single assessment at inclusion into study (serological testing)
Prevalence of neurocysticercosis
Prevalence of neurocysticercosis among people living with HIV and matched HIV-negative individuals in rural Tanzania where pig farming is common
Single assessment through cerebral CT scan at inclusion into study
Secondary Outcomes (1)
Th1 cytokines among neurocysticercosis patients
One time assessment through immunological testing at inclusion into study
Study Arms (2)
People living with HIV
People living with HIV (ART naive or on ART)
People not infected with HIV
HIV-negative people. Each participant is matched for age, sex and location to a study participant living with HIV
Interventions
* Serological tests for cysticercosis * Neurological examination and cerebral CT scan for the diagnosis of neurocysticercosis * Stool testing for T. solium
Eligibility Criteria
1000 patients from HIV clinics will be recruited at the study sites in Mbeya and Iringa region. For each HIV-positive patient an HIV-negative control matched by age, sex and location will be included.
You may qualify if:
- Patients who consent to participate in the study and testing.
- Patients of age 14 years and above
- Patient living inside the study catchment area
- HIV-positive patients
- Patient suspected of taeniasis or cysticercosis/neurocysticercosis
You may not qualify if:
- Patients with opportunistic infections.
- Study participants taking anthelminthic drugs PZQ and ALB or have received them within the previous 12 months.
- Pregnant women
- Patients that are seriously ill.
- Patients with epilepsy and other mental disorders that impair thoughts and emotions such as psychosis.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
National Institute of Medical Research
Dar es Salaam, Tanzania
Biospecimen
blood samples
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Bernard J Ngowi, MD, PhD
National Institute for Medical Research
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 4, 2019
First Posted
February 22, 2019
Study Start
April 1, 2018
Primary Completion
April 30, 2021
Study Completion
April 30, 2021
Last Updated
November 29, 2023
Record last verified: 2023-11